Product news

Share this article:
Biovail Corporation received FDA approval for its NDA for Aplenzin (formerly known as BVF-033), a once-daily formulation of bupropion hydrobromide developed by Biovail for the treatment of depression in adults. Biovail remains partnership discussions for the commercialization rights for Aplenzin in the US.

The FDA approved Shire's Vyvanse (lisdexamfetamine dimesylate) for the treatment of ADHD in adults.  Vyvanse was first introduced in July 2007 for the treatment of ADHD in children aged 6 to 12 years.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.